Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Table 2 Characteristics of 6 randomized trials comparing gemcitabine to gemcitabine plus fluoropyrimidine

Reference	Year	n	Treatment regimen	Stage IV (%)	Male (%)	PS 0–1 (%)
Berlin	2002	162	Gem 1000 mg/m² for 3 of 4 wks	90	54	86
		160	Gem 1000 mg/m² + 5-FU 600 mg/m² for 3 of 4 wks	89	52	86
Riess	2005	238	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	77	54	48*
		235	Gem 1000 mg/m² + FA 200 mg/m² 5-FU 750 mg/m² CI × 4 wks q 6 wks	77	52	44*
DiCostanzo	2005	48	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	73	48	69
		43	Gem 1000 mg/m² + CI 5-FU 200 mg/m² for 6 of 7 wks, then wkly for 3 of 4 wks	67	63	67
Scheithauer	2003	42	Gem 2200 mg/m² q 2 wks	100	55	24
		41	Gem 2200 mg/m² + Capecitabine 2500 mg/m² d1-7 q 2 wks	100	66	27
Herrmann	2005	159	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	79	53	53*
		160	Gem 1000 mg/m² d1, 8 + Capecitabine 2 × 650 mg/m² d1-14 q 3 wks	80	54	53*
Cunningham	2005	266	Gem 1000 mg/m² for 7 of 8 wks, then wkly for 3 of 4 wks	71	na	82
		267	Gem 1000 mg/m² d1, 8, 15 + Capecitabine 2 × 830 mg/m² d1-21 q 4 wks	70	na	81

ISSN: 1471-2407